DICE
Price:
$47.55
Market Cap:
$2.27B
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 int...[Read more]
Industry
Biotechnology
IPO Date
2021-09-15
Stock Exchange
NASDAQ
Ticker
DICE
According to DICE Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 38.14. This represents a change of 27.75% compared to the average of 29.85 of the last 4 quarters.
The mean historical Current Ratio of DICE Therapeutics, Inc. over the last ten years is 20.61. The current 38.14 Current Ratio has changed 18.41% with respect to the historical average. Over the past ten years (40 quarters), DICE's Current Ratio was at its highest in in the December 2022 quarter at 38.14. The Current Ratio was at its lowest in in the September 2020 quarter at 0.
Average
20.61
Median
18.81
Minimum
6.68
Maximum
38.14
Discovering the peaks and valleys of DICE Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 345.68%
Maximum Annual Current Ratio = 38.14
Minimum Annual Increase = -14.87%
Minimum Annual Current Ratio = 6.68
Year | Current Ratio | Change |
---|---|---|
2022 | 38.14 | 28.12% |
2021 | 29.77 | 345.68% |
2020 | 6.68 | -14.87% |
The current Current Ratio of DICE Therapeutics, Inc. (DICE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
24.86
5-year avg
20.61
10-year avg
20.61
DICE Therapeutics, Inc.’s Current Ratio is greater than Nuvalent, Inc. (23.07), greater than Arcellx, Inc. (4.29), greater than Vaxcyte, Inc. (17.88), greater than Viridian Therapeutics, Inc. (18.55), greater than Ventyx Biosciences, Inc. (23.52), greater than Immunocore Holdings plc (3.78), greater than Cytokinetics, Incorporated (9.28), greater than Edgewise Therapeutics, Inc. (26.35), greater than Karuna Therapeutics, Inc. (19.31), greater than Dyne Therapeutics, Inc. (17.02), greater than Chinook Therapeutics, Inc. (7.59), greater than Pliant Therapeutics, Inc. (10.26), greater than Crinetics Pharmaceuticals, Inc. (16.38), greater than Ascendis Pharma A/S (1.16), greater than Terns Pharmaceuticals, Inc. (32.99), greater than Day One Biopharmaceuticals, Inc. (14.62), greater than Acumen Pharmaceuticals, Inc. (10.43), greater than Amylyx Pharmaceuticals, Inc. (4.55), greater than MoonLake Immunotherapeutics (25.51),
Company | Current Ratio | Market cap |
---|---|---|
23.07 | $6.75B | |
4.29 | $4.89B | |
17.88 | $11.04B | |
18.55 | $1.60B | |
23.52 | $130.81M | |
3.78 | $1.61B | |
9.28 | $5.79B | |
26.35 | $3.05B | |
19.31 | $12.60B | |
17.02 | $3.02B | |
7.59 | $2.71B | |
10.26 | $789.88M | |
16.38 | $5.20B | |
1.16 | $7.76B | |
32.99 | $491.80M | |
14.62 | $1.38B | |
10.43 | $142.39M | |
4.55 | $361.25M | |
25.51 | $3.43B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like DICE Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like DICE Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is DICE Therapeutics, Inc.'s Current Ratio?
How is the Current Ratio calculated for DICE Therapeutics, Inc. (DICE)?
What is the highest Current Ratio for DICE Therapeutics, Inc. (DICE)?
What is the 3-year average Current Ratio for DICE Therapeutics, Inc. (DICE)?
What is the 5-year average Current Ratio for DICE Therapeutics, Inc. (DICE)?
How does the current Current Ratio for DICE Therapeutics, Inc. (DICE) compare to its historical average?